AskBio

AskBio is a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG. The company is dedicated to developing AAV gene therapies for genetic and complex disorders, with a particular focus on rare diseases. AskBio's clinical pipeline includes programs such as AB-1009 for late-onset Pompe disease (LOPD), which has received FDA Fast Track and Orphan Drug designations. The company emphasizes advancing genetic technology and AAV gene therapy platforms while working to lower production costs and increase supply for patients. AskBio engages with patients, families, care teams, and disease-advocacy organizations to inform its research and development priorities.